Clinical Research Directory
Browse clinical research sites, groups, and studies.
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
Sponsor: Crinetics Pharmaceuticals Inc.
Summary
This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Official title: A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-05-06
Completion Date
2026-12-31
Last Updated
2026-05-06
Healthy Volunteers
Yes
Conditions
Interventions
Atumelnant
Atumelnant, tablets
Carbamazepine
CYP3A4 inducer
Midazolam
CYP3A4 substrate
Digoxin
P-gp substrate
Metformin
MATE1/2-K substrate
Locations (1)
Crinetics Study Site
Lincoln, Nebraska, United States